aTyr Pharma Announces Participation at March Investor Conferences
March 04, 2019 17:36 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
February 27, 2019 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at the BIO CEO & Investor Conference
February 05, 2019 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
January 30, 2019 16:00 ET
|
aTyr Pharma, Inc.
Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of leading academic...
Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
January 16, 2019 16:00 ET
|
aTyr Pharma, Inc.
Researchers from The Hong Kong University of Science and Technology credited with important translational science and early discovery work Significant opportunity to replicate collaborative model to...
aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events
January 02, 2019 19:37 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
December 04, 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
November 28, 2018 20:16 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update
November 13, 2018 16:05 ET
|
aTyr Pharma, Inc.
- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 - - Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT – SAN DIEGO, Nov....
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
August 14, 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...